Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan

Author:

Matsunaga Nobuaki1,Hayakawa Kayoko12ORCID,Terada Mari23,Ohtsu Hiroshi3,Asai Yusuke1,Tsuzuki Shinya14,Suzuki Setsuko2,Toyoda Ako3,Suzuki Kumiko1,Endo Mio1,Fujii Naoki1,Suzuki Michiyo2,Saito Sho2,Uemura Yukari3,Shibata Taro5,Kondo Masashi6,Izumi Kazuo3,Terada-Hirashima Junko3,Mikami Ayako3,Sugiura Wataru3,Ohmagari Norio12

Affiliation:

1. AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan

2. Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan

3. Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

4. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

5. Biostatistics Division, Center for Research Administration and Support, National Cancer Center, Tokyo, Japan

6. Center for Clinical Trial and Research Support, Fujita Health University, Aichi, Japan

Abstract

Abstract Background There is limited understanding of the characteristics of patients with coronavirus disease 2019 (COVID-19) requiring hospitalization in Japan. Methods This study included 2638 cases enrolled from 227 healthcare facilities that participated in the COVID-19 Registry Japan (COVIREGI-JP). The inclusion criteria for enrollment of a case in COVIREGI-JP are both (1) a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test and (2) inpatient treatment at a healthcare facility. Results The median age of hospitalized patients with COVID-19 was 56 years (interquartile range [IQR], 40–71 years). More than half of cases were male (58.9%, 1542/2619). Nearly 60% of the cases had close contact to confirmed or suspected cases of COVID-19. The median duration of symptoms before admission was 7 days (IQR, 4–10 days). The most common comorbidities were hypertension (15%, 396/2638) and diabetes without complications (14.2%, 374/2638). The number of nonsevere cases (68.2%, n = 1798) was twice the number of severe cases (31.8%, n = 840) at admission. The respiratory support during hospitalization includes those who received no oxygen support (61.6%, 1623/2636) followed by those who received supplemental oxygen (29.9%, 788/2636) and invasive mechanical ventilation/extracorporeal membrane oxygenation (8.5%, 225/2636). Overall, 66.9% (1762/2634) of patients were discharged home, while 7.5% (197/2634) died. Conclusions We identified the clinical epidemiological features of COVID-19 in hospitalized patients in Japan. When compared with existing inpatient studies in other countries, these results demonstrated fewer comorbidities and a trend towards lower mortality.

Funder

Health and Labor Sciences Research

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference31 articles.

1. Clinical progression of patients with COVID-19 in Shanghai, China;Chen;J Infect,2020

2. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;Lancet,2020

3. Japanese strategy to COVID-19: How does it work?;Inoue;J Glob Health,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3